| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyotrophic Lateral Sclerosis | 32 | 2024 | 1459 | 2.600 |
Why?
|
| Parkinson Disease | 25 | 2024 | 2853 | 2.310 |
Why?
|
| Uric Acid | 14 | 2023 | 807 | 1.800 |
Why?
|
| Down Syndrome | 8 | 2022 | 891 | 1.050 |
Why?
|
| Neurofibromatoses | 7 | 2024 | 299 | 0.940 |
Why?
|
| Inosine | 8 | 2023 | 130 | 0.790 |
Why?
|
| Tai Ji | 6 | 2022 | 287 | 0.720 |
Why?
|
| Mind-Body Therapies | 7 | 2024 | 265 | 0.620 |
Why?
|
| Disease Progression | 17 | 2024 | 13505 | 0.600 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2022 | 1859 | 0.510 |
Why?
|
| Clinical Trials as Topic | 9 | 2024 | 8058 | 0.490 |
Why?
|
| Telemedicine | 7 | 2020 | 3005 | 0.490 |
Why?
|
| Quality of Life | 23 | 2024 | 13300 | 0.480 |
Why?
|
| Double-Blind Method | 31 | 2024 | 12412 | 0.430 |
Why?
|
| Research Design | 10 | 2024 | 6181 | 0.420 |
Why?
|
| Autistic Disorder | 3 | 2022 | 1213 | 0.420 |
Why?
|
| Resilience, Psychological | 4 | 2020 | 768 | 0.390 |
Why?
|
| Counseling | 1 | 2019 | 1550 | 0.380 |
Why?
|
| Antipsychotic Agents | 5 | 2018 | 3061 | 0.370 |
Why?
|
| Caregivers | 6 | 2022 | 2222 | 0.370 |
Why?
|
| Taurochenodeoxycholic Acid | 2 | 2020 | 35 | 0.360 |
Why?
|
| Relaxation Therapy | 3 | 2023 | 179 | 0.360 |
Why?
|
| Phenylbutyrates | 2 | 2020 | 72 | 0.350 |
Why?
|
| Metformin | 4 | 2019 | 912 | 0.350 |
Why?
|
| Humans | 179 | 2024 | 760261 | 0.330 |
Why?
|
| Acupuncture | 2 | 2006 | 90 | 0.330 |
Why?
|
| Male | 121 | 2024 | 359413 | 0.330 |
Why?
|
| Female | 129 | 2024 | 391011 | 0.320 |
Why?
|
| Mexiletine | 2 | 2020 | 31 | 0.320 |
Why?
|
| Quinidine | 2 | 2018 | 52 | 0.310 |
Why?
|
| Dextromethorphan | 2 | 2018 | 37 | 0.310 |
Why?
|
| Deglutition Disorders | 3 | 2019 | 627 | 0.290 |
Why?
|
| Health Status | 2 | 2017 | 4081 | 0.290 |
Why?
|
| Speech Disorders | 2 | 2019 | 180 | 0.280 |
Why?
|
| Thiazoles | 2 | 2018 | 1509 | 0.280 |
Why?
|
| Neuroprotective Agents | 3 | 2020 | 961 | 0.280 |
Why?
|
| Constipation | 5 | 2022 | 561 | 0.280 |
Why?
|
| Child Development Disorders, Pervasive | 4 | 2017 | 599 | 0.280 |
Why?
|
| Thalassemia | 4 | 2009 | 270 | 0.280 |
Why?
|
| Neurofibromatosis 2 | 2 | 2020 | 385 | 0.270 |
Why?
|
| Child | 50 | 2022 | 79758 | 0.270 |
Why?
|
| Polysomnography | 4 | 2022 | 1817 | 0.260 |
Why?
|
| Adolescent | 49 | 2022 | 87747 | 0.260 |
Why?
|
| Videoconferencing | 4 | 2020 | 203 | 0.260 |
Why?
|
| Single-Blind Method | 8 | 2023 | 1577 | 0.260 |
Why?
|
| Sample Size | 2 | 2019 | 840 | 0.250 |
Why?
|
| Caffeine | 2 | 2020 | 701 | 0.250 |
Why?
|
| Acupuncture Therapy | 4 | 2016 | 480 | 0.250 |
Why?
|
| Middle Aged | 72 | 2024 | 220175 | 0.250 |
Why?
|
| Antiparkinson Agents | 2 | 2023 | 183 | 0.240 |
Why?
|
| Anemia, Sickle Cell | 6 | 2015 | 1056 | 0.240 |
Why?
|
| Pilot Projects | 17 | 2024 | 8553 | 0.240 |
Why?
|
| Severity of Illness Index | 14 | 2022 | 15827 | 0.240 |
Why?
|
| Gastrointestinal Diseases | 4 | 2017 | 1189 | 0.240 |
Why?
|
| Treatment Outcome | 36 | 2024 | 64947 | 0.240 |
Why?
|
| Irritable Bowel Syndrome | 3 | 2022 | 452 | 0.240 |
Why?
|
| Schizophrenia | 7 | 2013 | 6915 | 0.230 |
Why?
|
| Adult | 68 | 2024 | 219847 | 0.230 |
Why?
|
| Speech | 2 | 2018 | 548 | 0.220 |
Why?
|
| Delayed Diagnosis | 2 | 2019 | 463 | 0.210 |
Why?
|
| Aged | 53 | 2024 | 168995 | 0.210 |
Why?
|
| Piperazines | 1 | 2013 | 2520 | 0.210 |
Why?
|
| Feasibility Studies | 6 | 2024 | 5201 | 0.200 |
Why?
|
| beta-Thalassemia | 3 | 2013 | 235 | 0.200 |
Why?
|
| Adaptation, Psychological | 7 | 2022 | 2628 | 0.200 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 2 | 2016 | 206 | 0.200 |
Why?
|
| Psychotherapy, Group | 2 | 2016 | 410 | 0.200 |
Why?
|
| Overweight | 4 | 2018 | 2421 | 0.190 |
Why?
|
| Deferoxamine | 3 | 2013 | 153 | 0.190 |
Why?
|
| Health Education | 2 | 2019 | 1049 | 0.190 |
Why?
|
| Phenytoin | 1 | 2022 | 188 | 0.190 |
Why?
|
| Patient Selection | 6 | 2024 | 4276 | 0.190 |
Why?
|
| Child, Preschool | 21 | 2022 | 42034 | 0.190 |
Why?
|
| Anticonvulsants | 3 | 2022 | 1881 | 0.190 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2021 | 415 | 0.190 |
Why?
|
| Iron Chelating Agents | 3 | 2013 | 138 | 0.190 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2018 | 1988 | 0.180 |
Why?
|
| Folic Acid | 3 | 2013 | 1309 | 0.180 |
Why?
|
| Face | 2 | 2017 | 1017 | 0.180 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2018 | 41 | 0.180 |
Why?
|
| Vital Capacity | 3 | 2019 | 965 | 0.180 |
Why?
|
| Chiropractic | 1 | 2020 | 39 | 0.180 |
Why?
|
| Stress, Psychological | 5 | 2022 | 4440 | 0.180 |
Why?
|
| Phenylenediamines | 1 | 2021 | 86 | 0.180 |
Why?
|
| Ferrous Compounds | 1 | 2019 | 41 | 0.170 |
Why?
|
| Nutritional Status | 3 | 2018 | 1606 | 0.170 |
Why?
|
| Carbamates | 1 | 2021 | 192 | 0.170 |
Why?
|
| Alkaloids | 1 | 2020 | 194 | 0.170 |
Why?
|
| Control Groups | 1 | 2019 | 105 | 0.160 |
Why?
|
| Evoked Potentials, Motor | 2 | 2020 | 461 | 0.160 |
Why?
|
| Hereditary Sensory and Autonomic Neuropathies | 1 | 2019 | 41 | 0.160 |
Why?
|
| Rectum | 2 | 2016 | 896 | 0.160 |
Why?
|
| Neurilemmoma | 1 | 2024 | 523 | 0.160 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2019 | 1076 | 0.150 |
Why?
|
| Dental Caries | 1 | 2022 | 420 | 0.150 |
Why?
|
| Alzheimer Disease | 3 | 2023 | 8551 | 0.150 |
Why?
|
| Dysarthria | 1 | 2017 | 58 | 0.150 |
Why?
|
| Cerebral Amyloid Angiopathy | 2 | 2015 | 892 | 0.150 |
Why?
|
| World Health Organization | 1 | 2024 | 1319 | 0.150 |
Why?
|
| Myography | 1 | 2018 | 111 | 0.150 |
Why?
|
| Stereotyped Behavior | 1 | 2018 | 135 | 0.150 |
Why?
|
| Pain Measurement | 3 | 2024 | 3514 | 0.150 |
Why?
|
| Depression | 6 | 2022 | 8033 | 0.140 |
Why?
|
| Creatine | 1 | 2019 | 426 | 0.140 |
Why?
|
| Bone Density | 5 | 2018 | 3528 | 0.140 |
Why?
|
| Antioxidants | 2 | 2016 | 1668 | 0.140 |
Why?
|
| Bone and Bones | 3 | 2017 | 2560 | 0.140 |
Why?
|
| Longitudinal Studies | 10 | 2020 | 14482 | 0.140 |
Why?
|
| Fractals | 1 | 2017 | 128 | 0.140 |
Why?
|
| Schizophrenic Psychology | 3 | 2013 | 1646 | 0.140 |
Why?
|
| Deglutition | 1 | 2018 | 208 | 0.140 |
Why?
|
| Compulsive Behavior | 1 | 2017 | 117 | 0.140 |
Why?
|
| Deafness | 1 | 2020 | 456 | 0.140 |
Why?
|
| General Adaptation Syndrome | 1 | 2016 | 7 | 0.130 |
Why?
|
| Spinal Cord | 2 | 2022 | 1817 | 0.130 |
Why?
|
| Superoxide Dismutase | 2 | 2022 | 594 | 0.130 |
Why?
|
| Public Housing | 1 | 2017 | 140 | 0.130 |
Why?
|
| alpha-Synuclein | 1 | 2022 | 749 | 0.130 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2016 | 148 | 0.130 |
Why?
|
| Motor Neurons | 1 | 2021 | 865 | 0.130 |
Why?
|
| Laxatives | 1 | 2016 | 90 | 0.130 |
Why?
|
| Motor Skills | 2 | 2017 | 520 | 0.130 |
Why?
|
| Oral Health | 1 | 2021 | 484 | 0.130 |
Why?
|
| Job Application | 1 | 2015 | 38 | 0.120 |
Why?
|
| Remission, Spontaneous | 1 | 2015 | 383 | 0.120 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 680 | 0.120 |
Why?
|
| Neural Stem Cells | 1 | 2022 | 884 | 0.120 |
Why?
|
| Hydrocortisone | 3 | 2016 | 1798 | 0.120 |
Why?
|
| Young Adult | 18 | 2024 | 58673 | 0.120 |
Why?
|
| Tamoxifen | 1 | 2019 | 963 | 0.120 |
Why?
|
| Cephalometry | 1 | 2016 | 382 | 0.120 |
Why?
|
| Independent Living | 1 | 2019 | 568 | 0.120 |
Why?
|
| Mind-Body Relations, Metaphysical | 1 | 2014 | 36 | 0.120 |
Why?
|
| Serine | 1 | 2019 | 831 | 0.120 |
Why?
|
| Isothiocyanates | 1 | 2014 | 48 | 0.120 |
Why?
|
| Parents | 6 | 2022 | 3547 | 0.120 |
Why?
|
| Chorionic Villi Sampling | 1 | 2014 | 35 | 0.120 |
Why?
|
| Health | 1 | 2017 | 395 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2019 | 1181 | 0.120 |
Why?
|
| Critical Illness | 2 | 2020 | 2709 | 0.120 |
Why?
|
| Hirschsprung Disease | 1 | 2016 | 163 | 0.120 |
Why?
|
| Follow-Up Studies | 16 | 2020 | 39254 | 0.120 |
Why?
|
| Electric Impedance | 1 | 2018 | 751 | 0.120 |
Why?
|
| Anxiety | 4 | 2020 | 4532 | 0.120 |
Why?
|
| Polydactyly | 1 | 2014 | 56 | 0.120 |
Why?
|
| Inservice Training | 1 | 2016 | 376 | 0.110 |
Why?
|
| Skin Neoplasms | 2 | 2024 | 5797 | 0.110 |
Why?
|
| Social Behavior | 2 | 2018 | 1130 | 0.110 |
Why?
|
| Child Behavior | 2 | 2022 | 848 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2015 | 2689 | 0.110 |
Why?
|
| Nutritional Requirements | 1 | 2015 | 275 | 0.110 |
Why?
|
| Postural Balance | 2 | 2016 | 617 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2021 | 1056 | 0.110 |
Why?
|
| Corpus Striatum | 1 | 2020 | 1233 | 0.110 |
Why?
|
| Communication | 2 | 2018 | 3846 | 0.110 |
Why?
|
| Benzhydryl Compounds | 2 | 2011 | 942 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2013 | 58 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2019 | 629 | 0.110 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2011 | 275 | 0.110 |
Why?
|
| Personnel Selection | 1 | 2015 | 193 | 0.110 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 413 | 0.110 |
Why?
|
| Siderophores | 1 | 2013 | 61 | 0.110 |
Why?
|
| Axons | 1 | 2020 | 1672 | 0.100 |
Why?
|
| Blood Volume Determination | 1 | 2012 | 41 | 0.100 |
Why?
|
| Memory Disorders | 2 | 2010 | 1197 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2023 | 10340 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 1395 | 0.100 |
Why?
|
| Levodopa | 2 | 2023 | 217 | 0.100 |
Why?
|
| Comorbidity | 4 | 2022 | 10552 | 0.100 |
Why?
|
| Blood Pressure | 4 | 2018 | 8523 | 0.100 |
Why?
|
| Cerebral Cortex | 2 | 2021 | 5755 | 0.100 |
Why?
|
| Micronutrients | 1 | 2015 | 380 | 0.100 |
Why?
|
| Hypokalemia | 1 | 2013 | 153 | 0.100 |
Why?
|
| Hearing Loss | 1 | 2019 | 780 | 0.100 |
Why?
|
| Gait | 1 | 2017 | 812 | 0.100 |
Why?
|
| Skull | 1 | 2016 | 815 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2013 | 6017 | 0.100 |
Why?
|
| Weight Gain | 2 | 2019 | 2347 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 1799 | 0.100 |
Why?
|
| Maternal Age | 1 | 2014 | 807 | 0.100 |
Why?
|
| Gout | 1 | 2018 | 619 | 0.100 |
Why?
|
| Serotonin | 1 | 2016 | 1041 | 0.090 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 749 | 0.090 |
Why?
|
| Fatigue | 3 | 2017 | 1544 | 0.090 |
Why?
|
| Hyperkalemia | 1 | 2013 | 231 | 0.090 |
Why?
|
| Antimetabolites | 1 | 2011 | 127 | 0.090 |
Why?
|
| Blood Volume | 1 | 2012 | 550 | 0.090 |
Why?
|
| Hypoglycemic Agents | 3 | 2019 | 3149 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2021 | 3822 | 0.090 |
Why?
|
| Cycloserine | 1 | 2011 | 118 | 0.090 |
Why?
|
| Psychotherapy | 1 | 2019 | 1640 | 0.090 |
Why?
|
| Educational Measurement | 1 | 2017 | 1249 | 0.090 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 2010 | 47 | 0.090 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 298 | 0.090 |
Why?
|
| Posture | 1 | 2014 | 954 | 0.090 |
Why?
|
| Colon, Sigmoid | 1 | 2010 | 124 | 0.090 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 350 | 0.090 |
Why?
|
| Pelvic Organ Prolapse | 1 | 2012 | 133 | 0.090 |
Why?
|
| Vitamin B 12 | 1 | 2013 | 522 | 0.090 |
Why?
|
| Embryo Transfer | 2 | 2011 | 521 | 0.090 |
Why?
|
| Stroke | 5 | 2015 | 9945 | 0.090 |
Why?
|
| Cross-Sectional Studies | 11 | 2022 | 25928 | 0.090 |
Why?
|
| Kluver-Bucy Syndrome | 1 | 2009 | 9 | 0.090 |
Why?
|
| Outpatients | 3 | 2017 | 1606 | 0.080 |
Why?
|
| AIDS Vaccines | 1 | 2016 | 896 | 0.080 |
Why?
|
| Psychopathology | 1 | 2012 | 427 | 0.080 |
Why?
|
| Bayes Theorem | 3 | 2023 | 2325 | 0.080 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2010 | 122 | 0.080 |
Why?
|
| Clozapine | 2 | 2011 | 506 | 0.080 |
Why?
|
| Tibia | 2 | 2017 | 1065 | 0.080 |
Why?
|
| Hypertension | 2 | 2006 | 8595 | 0.080 |
Why?
|
| Embryo Implantation | 1 | 2011 | 270 | 0.080 |
Why?
|
| Delusions | 1 | 2011 | 298 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2019 | 2627 | 0.080 |
Why?
|
| Intelligence Tests | 2 | 2022 | 498 | 0.080 |
Why?
|
| Long QT Syndrome | 1 | 2013 | 465 | 0.080 |
Why?
|
| Dementia | 1 | 2023 | 2638 | 0.080 |
Why?
|
| Infertility, Female | 1 | 2014 | 760 | 0.080 |
Why?
|
| Cryopreservation | 2 | 2011 | 720 | 0.080 |
Why?
|
| Drug Combinations | 3 | 2020 | 2024 | 0.080 |
Why?
|
| Vitamin B Complex | 1 | 2011 | 297 | 0.080 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2015 | 2421 | 0.080 |
Why?
|
| Community Health Services | 1 | 2014 | 654 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 326 | 0.080 |
Why?
|
| Cytokines | 2 | 2021 | 7345 | 0.080 |
Why?
|
| Organs at Risk | 1 | 2010 | 358 | 0.080 |
Why?
|
| Seizures | 2 | 2020 | 2916 | 0.080 |
Why?
|
| Career Choice | 1 | 2015 | 755 | 0.080 |
Why?
|
| Chronic Disease | 4 | 2019 | 9283 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2015 | 1500 | 0.080 |
Why?
|
| Circumcision, Male | 1 | 2010 | 149 | 0.080 |
Why?
|
| Neural Conduction | 2 | 2020 | 441 | 0.080 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2010 | 255 | 0.080 |
Why?
|
| Carbamazepine | 2 | 2022 | 224 | 0.080 |
Why?
|
| Models, Cardiovascular | 1 | 2013 | 974 | 0.080 |
Why?
|
| Memory | 1 | 2018 | 2179 | 0.080 |
Why?
|
| Polymorphism, Genetic | 3 | 2019 | 4286 | 0.080 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2008 | 41 | 0.080 |
Why?
|
| Enteral Nutrition | 1 | 2014 | 781 | 0.080 |
Why?
|
| Time Factors | 9 | 2023 | 40133 | 0.070 |
Why?
|
| Migraine Disorders | 1 | 2020 | 1693 | 0.070 |
Why?
|
| Pyridones | 1 | 2013 | 788 | 0.070 |
Why?
|
| Age Factors | 9 | 2017 | 18415 | 0.070 |
Why?
|
| Oxidants | 1 | 2008 | 169 | 0.070 |
Why?
|
| Prospective Studies | 12 | 2020 | 54263 | 0.070 |
Why?
|
| Intention to Treat Analysis | 2 | 2020 | 422 | 0.070 |
Why?
|
| Poverty | 1 | 2019 | 2695 | 0.070 |
Why?
|
| Prenatal Diagnosis | 1 | 2014 | 1262 | 0.070 |
Why?
|
| Genotype | 5 | 2019 | 12959 | 0.070 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2011 | 475 | 0.070 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 58947 | 0.070 |
Why?
|
| Facial Pain | 1 | 2008 | 120 | 0.070 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 1504 | 0.070 |
Why?
|
| Retrospective Studies | 19 | 2023 | 80301 | 0.070 |
Why?
|
| Ambrosia | 1 | 2006 | 6 | 0.070 |
Why?
|
| Colonoscopy | 1 | 2015 | 1387 | 0.070 |
Why?
|
| Hemiplegia | 1 | 2007 | 136 | 0.070 |
Why?
|
| Cognition | 4 | 2018 | 6948 | 0.070 |
Why?
|
| Infant | 10 | 2017 | 36030 | 0.070 |
Why?
|
| Oxidative Stress | 2 | 2016 | 3107 | 0.070 |
Why?
|
| Cohort Studies | 12 | 2020 | 41317 | 0.070 |
Why?
|
| Benzoates | 1 | 2008 | 212 | 0.070 |
Why?
|
| Vitamin D | 2 | 2018 | 3293 | 0.070 |
Why?
|
| Analysis of Variance | 5 | 2016 | 6242 | 0.070 |
Why?
|
| Carcinoma, Papillary | 1 | 2011 | 785 | 0.070 |
Why?
|
| Pollen | 1 | 2006 | 82 | 0.070 |
Why?
|
| Fertilization in Vitro | 2 | 2011 | 1292 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 4044 | 0.070 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2013 | 1013 | 0.070 |
Why?
|
| Internship and Residency | 2 | 2017 | 5867 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 7803 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 2753 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2014 | 1180 | 0.060 |
Why?
|
| Fertility | 1 | 2010 | 772 | 0.060 |
Why?
|
| Self Efficacy | 2 | 2022 | 629 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2009 | 560 | 0.060 |
Why?
|
| Cognition Disorders | 3 | 2015 | 3976 | 0.060 |
Why?
|
| Pueraria | 1 | 2005 | 13 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 3967 | 0.060 |
Why?
|
| Physical Fitness | 2 | 2023 | 732 | 0.060 |
Why?
|
| Ferritins | 3 | 2019 | 598 | 0.060 |
Why?
|
| Bone Diseases | 1 | 2009 | 418 | 0.060 |
Why?
|
| Alcohol Deterrents | 1 | 2005 | 48 | 0.060 |
Why?
|
| Gadolinium | 1 | 2010 | 959 | 0.060 |
Why?
|
| Electromyography | 2 | 2020 | 1386 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 619 | 0.060 |
Why?
|
| Family | 1 | 2015 | 3189 | 0.060 |
Why?
|
| Absorptiometry, Photon | 3 | 2018 | 1731 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2016 | 2730 | 0.060 |
Why?
|
| Paresis | 1 | 2005 | 177 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 4168 | 0.060 |
Why?
|
| Metabolic Diseases | 1 | 2011 | 685 | 0.060 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2010 | 556 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2010 | 1166 | 0.060 |
Why?
|
| United States | 10 | 2024 | 72363 | 0.060 |
Why?
|
| Asthma | 3 | 2008 | 6167 | 0.060 |
Why?
|
| Growth Disorders | 1 | 2009 | 654 | 0.060 |
Why?
|
| Endpoint Determination | 2 | 2022 | 597 | 0.060 |
Why?
|
| Biopsy | 1 | 2016 | 6775 | 0.060 |
Why?
|
| Hydrazones | 1 | 2024 | 102 | 0.060 |
Why?
|
| Intensive Care Units | 3 | 2022 | 3737 | 0.060 |
Why?
|
| Pain | 3 | 2009 | 5066 | 0.060 |
Why?
|
| Cerebral Angiography | 1 | 2009 | 1272 | 0.060 |
Why?
|
| Muscle Strength | 2 | 2019 | 619 | 0.060 |
Why?
|
| Heart Failure | 3 | 2013 | 11835 | 0.060 |
Why?
|
| Cerebral Hemorrhage | 1 | 2015 | 2660 | 0.060 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2023 | 23 | 0.060 |
Why?
|
| Low Back Pain | 1 | 2012 | 979 | 0.060 |
Why?
|
| Sex Factors | 5 | 2020 | 10530 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 4923 | 0.050 |
Why?
|
| Case-Control Studies | 5 | 2020 | 22041 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2010 | 1183 | 0.050 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2016 | 2494 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 10829 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 17766 | 0.050 |
Why?
|
| Phytotherapy | 1 | 2005 | 295 | 0.050 |
Why?
|
| Brachytherapy | 1 | 2010 | 1240 | 0.050 |
Why?
|
| Heterozygote | 2 | 2020 | 2797 | 0.050 |
Why?
|
| Mental Health | 1 | 2017 | 3206 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2019 | 454 | 0.050 |
Why?
|
| Canada | 2 | 2020 | 2128 | 0.050 |
Why?
|
| Triazoles | 1 | 2008 | 904 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 2359 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 1902 | 0.050 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2022 | 66 | 0.050 |
Why?
|
| Psychotic Disorders | 3 | 2012 | 3175 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 4547 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2011 | 1434 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2015 | 36247 | 0.050 |
Why?
|
| Chest Pain | 2 | 2007 | 1106 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2013 | 7016 | 0.050 |
Why?
|
| Community-Based Participatory Research | 1 | 2024 | 221 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2015 | 3839 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2015 | 3389 | 0.050 |
Why?
|
| Neurofilament Proteins | 1 | 2024 | 333 | 0.050 |
Why?
|
| Glutamate Carboxypeptidase II | 2 | 2013 | 81 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2017 | 5073 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2014 | 3185 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 2880 | 0.050 |
Why?
|
| Carbon Dioxide | 1 | 2006 | 1145 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 2940 | 0.050 |
Why?
|
| Brain Neoplasms | 3 | 2020 | 8984 | 0.050 |
Why?
|
| Weight Loss | 1 | 2013 | 2683 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2023 | 238 | 0.050 |
Why?
|
| Tremor | 1 | 2022 | 187 | 0.050 |
Why?
|
| Morpholines | 1 | 2024 | 583 | 0.050 |
Why?
|
| Phenobarbital | 1 | 2022 | 190 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2014 | 6545 | 0.050 |
Why?
|
| Diet | 2 | 2018 | 8008 | 0.050 |
Why?
|
| Manipulation, Spinal | 1 | 2020 | 21 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2016 | 12762 | 0.050 |
Why?
|
| Central Nervous System Stimulants | 1 | 2009 | 1169 | 0.050 |
Why?
|
| Disease-Free Survival | 4 | 2013 | 6830 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2005 | 661 | 0.050 |
Why?
|
| Survivors | 2 | 2021 | 2367 | 0.040 |
Why?
|
| Theophylline | 1 | 2020 | 131 | 0.040 |
Why?
|
| Xanthines | 1 | 2020 | 122 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2012 | 2776 | 0.040 |
Why?
|
| Median Nerve | 1 | 2020 | 132 | 0.040 |
Why?
|
| Body Weight | 1 | 2011 | 4613 | 0.040 |
Why?
|
| Interleukin-2 | 2 | 2022 | 1890 | 0.040 |
Why?
|
| Oral Hygiene | 1 | 2021 | 129 | 0.040 |
Why?
|
| Seasons | 1 | 2006 | 1523 | 0.040 |
Why?
|
| Electrodiagnosis | 1 | 2020 | 148 | 0.040 |
Why?
|
| Brain Infarction | 1 | 2002 | 292 | 0.040 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2019 | 30 | 0.040 |
Why?
|
| Intracranial Aneurysm | 1 | 2009 | 1276 | 0.040 |
Why?
|
| Social Support | 1 | 2009 | 2145 | 0.040 |
Why?
|
| Housing for the Elderly | 1 | 2019 | 16 | 0.040 |
Why?
|
| Prognosis | 5 | 2024 | 29636 | 0.040 |
Why?
|
| Motor Cortex | 1 | 2007 | 995 | 0.040 |
Why?
|
| Vitamin D Deficiency | 1 | 2009 | 1381 | 0.040 |
Why?
|
| Viral Load | 1 | 2008 | 3323 | 0.040 |
Why?
|
| Registries | 1 | 2015 | 8449 | 0.040 |
Why?
|
| ROC Curve | 2 | 2017 | 3568 | 0.040 |
Why?
|
| Antihypertensive Agents | 2 | 2006 | 2063 | 0.040 |
Why?
|
| Cocaine | 1 | 2004 | 961 | 0.040 |
Why?
|
| Epilepsy | 2 | 2016 | 3267 | 0.040 |
Why?
|
| Statistics as Topic | 2 | 2019 | 2363 | 0.040 |
Why?
|
| Dental Care | 1 | 2022 | 278 | 0.040 |
Why?
|
| Linear Models | 4 | 2011 | 5876 | 0.040 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2019 | 42 | 0.040 |
Why?
|
| Speech Therapy | 1 | 2019 | 57 | 0.040 |
Why?
|
| Communication Aids for Disabled | 1 | 2019 | 56 | 0.040 |
Why?
|
| Muscles | 1 | 2023 | 1581 | 0.040 |
Why?
|
| Time | 1 | 2020 | 545 | 0.040 |
Why?
|
| Inpatients | 1 | 2010 | 2578 | 0.040 |
Why?
|
| Disability Evaluation | 2 | 2019 | 1826 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 3159 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 696 | 0.040 |
Why?
|
| Exercise | 3 | 2023 | 5783 | 0.040 |
Why?
|
| Brain Ischemia | 1 | 2012 | 3127 | 0.040 |
Why?
|
| Reproducibility of Results | 5 | 2016 | 20048 | 0.040 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2010 | 2018 | 0.040 |
Why?
|
| Mental Recall | 1 | 2004 | 1205 | 0.040 |
Why?
|
| Placebos | 2 | 2014 | 1672 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 2414 | 0.040 |
Why?
|
| Pregnancy Rate | 2 | 2011 | 650 | 0.040 |
Why?
|
| HIV Infections | 3 | 2016 | 17159 | 0.040 |
Why?
|
| Emotions | 2 | 2022 | 2730 | 0.040 |
Why?
|
| Mutation | 2 | 2019 | 29950 | 0.040 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 6499 | 0.040 |
Why?
|
| Regression Analysis | 3 | 2014 | 6361 | 0.040 |
Why?
|
| Asperger Syndrome | 1 | 2017 | 56 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2015 | 4763 | 0.040 |
Why?
|
| Sphingolipids | 1 | 2019 | 173 | 0.040 |
Why?
|
| Kidney Calculi | 1 | 2021 | 468 | 0.040 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 15273 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 11902 | 0.040 |
Why?
|
| Contrast Media | 1 | 2010 | 5301 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2013 | 4668 | 0.030 |
Why?
|
| Minority Groups | 1 | 2024 | 1199 | 0.030 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 12532 | 0.030 |
Why?
|
| Radiography, Dental | 1 | 2016 | 54 | 0.030 |
Why?
|
| Isometric Contraction | 1 | 2017 | 146 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 987 | 0.030 |
Why?
|
| Lung | 1 | 2015 | 9989 | 0.030 |
Why?
|
| Pregnancy | 5 | 2022 | 29725 | 0.030 |
Why?
|
| Educational Status | 1 | 2024 | 2512 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2011 | 6375 | 0.030 |
Why?
|
| Muscle Cramp | 1 | 2016 | 34 | 0.030 |
Why?
|
| Parenting | 1 | 2022 | 695 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 3242 | 0.030 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2018 | 225 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2017 | 2061 | 0.030 |
Why?
|
| Injections, Intradermal | 1 | 2016 | 116 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 4355 | 0.030 |
Why?
|
| Malocclusion | 1 | 2016 | 131 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2020 | 643 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 14656 | 0.030 |
Why?
|
| Laboratories | 1 | 2019 | 461 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2016 | 123 | 0.030 |
Why?
|
| Doxorubicin | 2 | 2013 | 2207 | 0.030 |
Why?
|
| Bradycardia | 1 | 2017 | 298 | 0.030 |
Why?
|
| Financing, Government | 1 | 2019 | 472 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2010 | 3482 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2019 | 824 | 0.030 |
Why?
|
| Endocrine System | 1 | 2016 | 112 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2021 | 2646 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 2010 | 3202 | 0.030 |
Why?
|
| Sulfoxides | 1 | 2014 | 46 | 0.030 |
Why?
|
| Prevalence | 5 | 2015 | 15687 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2008 | 4554 | 0.030 |
Why?
|
| Aftercare | 1 | 2021 | 918 | 0.030 |
Why?
|
| Paclitaxel | 2 | 2013 | 1738 | 0.030 |
Why?
|
| Alcoholism | 1 | 2005 | 1961 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 11708 | 0.030 |
Why?
|
| Psychometrics | 1 | 2024 | 3049 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2016 | 429 | 0.030 |
Why?
|
| Attention | 1 | 2004 | 2386 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2024 | 1992 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 857 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2018 | 1161 | 0.030 |
Why?
|
| Triazines | 1 | 2016 | 310 | 0.030 |
Why?
|
| Glioma | 1 | 2009 | 3420 | 0.030 |
Why?
|
| Radius | 1 | 2017 | 440 | 0.030 |
Why?
|
| Diet Records | 1 | 2015 | 427 | 0.030 |
Why?
|
| Risk Factors | 8 | 2020 | 74269 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2005 | 2041 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 2192 | 0.030 |
Why?
|
| Valproic Acid | 1 | 2016 | 442 | 0.030 |
Why?
|
| Renal Insufficiency | 2 | 2010 | 820 | 0.030 |
Why?
|
| PubMed | 1 | 2013 | 128 | 0.030 |
Why?
|
| Eating | 1 | 2020 | 1538 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2010 | 20484 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2015 | 9712 | 0.030 |
Why?
|
| Lebanon | 1 | 2013 | 245 | 0.030 |
Why?
|
| Group Processes | 1 | 2014 | 226 | 0.030 |
Why?
|
| Intelligence | 1 | 2017 | 919 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2013 | 316 | 0.030 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2012 | 85 | 0.030 |
Why?
|
| Logistic Models | 3 | 2013 | 13311 | 0.030 |
Why?
|
| Ontario | 1 | 2013 | 405 | 0.030 |
Why?
|
| Reduced Folate Carrier Protein | 1 | 2011 | 9 | 0.030 |
Why?
|
| Spirometry | 1 | 2015 | 924 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2024 | 3011 | 0.030 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2011 | 12 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2019 | 2698 | 0.030 |
Why?
|
| Health Services | 1 | 2017 | 754 | 0.020 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2011 | 28 | 0.020 |
Why?
|
| Boston | 2 | 2016 | 9282 | 0.020 |
Why?
|
| North America | 2 | 2005 | 1282 | 0.020 |
Why?
|
| Infant, Newborn | 5 | 2014 | 26168 | 0.020 |
Why?
|
| Mandible | 1 | 2016 | 749 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2017 | 2932 | 0.020 |
Why?
|
| Fasting | 1 | 2018 | 1603 | 0.020 |
Why?
|
| Immunization | 1 | 2016 | 1228 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2019 | 1405 | 0.020 |
Why?
|
| Physical Examination | 1 | 2017 | 1244 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2016 | 4357 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2024 | 2477 | 0.020 |
Why?
|
| Age Distribution | 2 | 2009 | 2893 | 0.020 |
Why?
|
| Observer Variation | 1 | 2017 | 2596 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 18134 | 0.020 |
Why?
|
| Motivation | 1 | 2021 | 1990 | 0.020 |
Why?
|
| Metabolomics | 1 | 2020 | 1626 | 0.020 |
Why?
|
| HIV-1 | 1 | 2008 | 6850 | 0.020 |
Why?
|
| Medical Order Entry Systems | 1 | 2016 | 522 | 0.020 |
Why?
|
| Calcium | 2 | 2018 | 5726 | 0.020 |
Why?
|
| Cardiovascular System | 1 | 2018 | 850 | 0.020 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2020 | 1469 | 0.020 |
Why?
|
| Health Behavior | 1 | 2022 | 2621 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2015 | 1810 | 0.020 |
Why?
|
| Checklist | 1 | 2017 | 827 | 0.020 |
Why?
|
| Recovery of Function | 2 | 2013 | 2982 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2012 | 632 | 0.020 |
Why?
|
| Pregnancy Outcome | 2 | 2011 | 2906 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2017 | 1430 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 3804 | 0.020 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2011 | 251 | 0.020 |
Why?
|
| Twins | 1 | 2011 | 339 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2017 | 1054 | 0.020 |
Why?
|
| Urban Population | 1 | 2017 | 2021 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2008 | 5201 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2015 | 817 | 0.020 |
Why?
|
| Somatomedins | 1 | 2009 | 178 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 881 | 0.020 |
Why?
|
| Executive Function | 1 | 2017 | 1370 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2022 | 3076 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2013 | 826 | 0.020 |
Why?
|
| Carboplatin | 1 | 2011 | 789 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 26912 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 1008 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 1723 | 0.020 |
Why?
|
| Acupuncture Analgesia | 1 | 2008 | 63 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2009 | 208 | 0.020 |
Why?
|
| Disease Management | 1 | 2019 | 2508 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2016 | 12901 | 0.020 |
Why?
|
| Transfection | 1 | 2016 | 5782 | 0.020 |
Why?
|
| Cell Degranulation | 1 | 2008 | 278 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2021 | 3475 | 0.020 |
Why?
|
| Phenotype | 3 | 2017 | 16543 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2012 | 601 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 2311 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 1840 | 0.020 |
Why?
|
| Culture | 1 | 2011 | 622 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2008 | 271 | 0.020 |
Why?
|
| Joints | 1 | 2009 | 321 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 493 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2009 | 956 | 0.020 |
Why?
|
| Growth Hormone | 1 | 2009 | 568 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 788 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2017 | 2283 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 345 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2009 | 15680 | 0.020 |
Why?
|
| Animals | 4 | 2022 | 167940 | 0.020 |
Why?
|
| Social Isolation | 1 | 2009 | 362 | 0.020 |
Why?
|
| Health Personnel | 1 | 2020 | 3310 | 0.020 |
Why?
|
| Atmosphere | 1 | 2006 | 32 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 659 | 0.020 |
Why?
|
| Education | 1 | 2009 | 535 | 0.020 |
Why?
|
| Energy Intake | 1 | 2014 | 2128 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3466 | 0.020 |
Why?
|
| Cadaver | 1 | 2010 | 1345 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2016 | 3207 | 0.020 |
Why?
|
| Models, Economic | 1 | 2010 | 719 | 0.020 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2010 | 470 | 0.020 |
Why?
|
| Natural Language Processing | 1 | 2015 | 1136 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 21065 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3598 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 2220 | 0.020 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2009 | 387 | 0.020 |
Why?
|
| Climate | 1 | 2006 | 147 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2009 | 943 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 2945 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 9196 | 0.020 |
Why?
|
| Vagina | 1 | 2010 | 842 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2009 | 10185 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2009 | 580 | 0.020 |
Why?
|
| Beer | 1 | 2005 | 134 | 0.020 |
Why?
|
| Ascorbic Acid | 1 | 2008 | 655 | 0.020 |
Why?
|
| Muscle Spasticity | 1 | 2005 | 155 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 3531 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2010 | 1001 | 0.020 |
Why?
|
| Cholesterol | 1 | 2014 | 2925 | 0.010 |
Why?
|
| Heart Rate | 1 | 2016 | 4169 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2011 | 3605 | 0.010 |
Why?
|
| Siblings | 1 | 2008 | 825 | 0.010 |
Why?
|
| Catheterization | 1 | 2009 | 1432 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2019 | 8018 | 0.010 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2008 | 865 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 2897 | 0.010 |
Why?
|
| Organ Size | 1 | 2009 | 2249 | 0.010 |
Why?
|
| Vitamin E | 1 | 2008 | 872 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 3696 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2018 | 14396 | 0.010 |
Why?
|
| Rabbits | 1 | 2009 | 4773 | 0.010 |
Why?
|
| Hypogonadism | 1 | 2009 | 800 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2015 | 3561 | 0.010 |
Why?
|
| Memory, Short-Term | 1 | 2009 | 977 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 2009 | 1797 | 0.010 |
Why?
|
| Inflammation | 1 | 2022 | 10757 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2009 | 2253 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5324 | 0.010 |
Why?
|
| Wakefulness | 1 | 2009 | 1253 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2011 | 2563 | 0.010 |
Why?
|
| Spinal Fractures | 1 | 2009 | 698 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2009 | 2656 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 2811 | 0.010 |
Why?
|
| Massachusetts | 1 | 2015 | 8805 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2010 | 1660 | 0.010 |
Why?
|
| Iron Overload | 1 | 2004 | 240 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2017 | 4786 | 0.010 |
Why?
|
| Endocrine System Diseases | 1 | 2004 | 251 | 0.010 |
Why?
|
| Plant Extracts | 1 | 2005 | 495 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2009 | 1876 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2009 | 1957 | 0.010 |
Why?
|
| Artifacts | 1 | 2009 | 1893 | 0.010 |
Why?
|
| Sleep | 1 | 2017 | 4746 | 0.010 |
Why?
|
| Virus Replication | 1 | 2008 | 2431 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 4900 | 0.010 |
Why?
|
| Task Performance and Analysis | 1 | 2004 | 759 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2013 | 24086 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 3870 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2008 | 2837 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2008 | 3160 | 0.010 |
Why?
|
| Hospitalization | 1 | 2020 | 10761 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2001 | 11891 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 8551 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2009 | 1416 | 0.010 |
Why?
|
| Length of Stay | 1 | 2013 | 6472 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 2731 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2013 | 5513 | 0.010 |
Why?
|
| Range of Motion, Articular | 1 | 2005 | 1582 | 0.010 |
Why?
|
| Neurosurgical Procedures | 1 | 2009 | 2056 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 2804 | 0.010 |
Why?
|
| Papillomavirus Infections | 1 | 2010 | 1600 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 3335 | 0.010 |
Why?
|
| Incidence | 1 | 2015 | 21378 | 0.010 |
Why?
|
| Survival Rate | 1 | 2011 | 12806 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 5507 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2010 | 3257 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 11141 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2010 | 6210 | 0.010 |
Why?
|
| Cause of Death | 1 | 2007 | 3723 | 0.010 |
Why?
|
| Acute Disease | 1 | 2007 | 7268 | 0.010 |
Why?
|
| Iron | 1 | 2004 | 1786 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2002 | 1328 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2009 | 4374 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2004 | 1925 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 8945 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 7468 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12156 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 15766 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 5884 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 12602 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 81216 | 0.010 |
Why?
|
| Obesity | 1 | 2013 | 12915 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2004 | 2809 | 0.010 |
Why?
|
| Aging | 1 | 2009 | 8641 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 8487 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 7512 | 0.000 |
Why?
|